JP Morgan Chase
LBRX

JP Morgan Chase’s LB Pharmaceuticals LBRX Stock Holding History

JP Morgan Chase’s Portfolio LBRX Stock Details LBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$33.2M Sell
1,427,568
-183,914
-11% -$4.24M ﹤0.01% 1661
2025
Q4 		$35.9M Buy
1,611,482
+578,879
+56% +$10.1M ﹤0.01% 1589
2025
Q3 		$16.3M Buy
+1,032,603
New +$16.4M ﹤0.01% 2266

Other funds holding LBRX

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

JP Morgan Chase's LBRX Position: Q1 2026 in Review

JP Morgan Chase reduced its LB Pharmaceuticals (LBRX) stake by 11% in Q1 2026, selling an estimated $4.24M and leaving 1,427,568 shares worth $33.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1661.

JP Morgan Chase first reported a position in LBRX in Q3 2025 and has held it in 3 quarters since. The position peaked at $35.9M in Q4 2025. 77 funds tracked by Wall St. Rank hold LBRX as of Q1 2026.

  • JP Morgan Chase held 1,427,568 shares of LB Pharmaceuticals worth $33.2M as of Q1 2026.
  • JP Morgan Chase sold 183,914 LB Pharmaceuticals shares in Q1 2026, an estimated $4.24M.
  • LB Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #1661 holding.
  • JP Morgan Chase first reported a position in LB Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • JP Morgan Chase's LB Pharmaceuticals position peaked at $35.9M in Q4 2025.
  • 77 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.